In pharmaceutical development, the final step—packaging—is often treated as a logistical formality. However, for high-potency oral solid dose products, it is a critical function that directly impacts product integrity, regulatory compliance, and time-to-market. At Eirgen, we have made a strategic investment in bringing packaging in-house at our Westside Business Park site in Waterford. This decision has allowed us to maintain full control over the final stage of the product lifecycle, reducing complexity and accelerating delivery timelines for our partners.

The Importance of In-House Packaging

Unlike many Contract Development and Manufacturing Organizations (CDMOs) that rely on external packaging vendors, Eirgen's integrated model eliminates the delays and risks associated with off-site transfers. Our packaging operations are fully embedded within our high-containment manufacturing environment. This enables a seamless transition from production to finished supply chain, which is particularly important for high-potency compounds where containment and compliance requirements are stringent.

Advanced Packaging Capabilities

Our primary packaging capabilities include the ACG High Speed BMAX Blister Machine. This machine supports both thermoform and cold-form blistering. It handles a wide range of dosage forms with consistent quality and high throughput, making it well-suited for commercial volumes. For products requiring unit-dose formats or individual containment, our Effytec Sachet Packer offers flexible packaging for powders and granules, operating under conditions appropriate for HPAPI handling. Both systems are designed to support rapid turnaround without compromising safety or regulatory standards.

ACG BMax Blister Machine

Streamlined Secondary Packaging

Secondary packaging is equally streamlined. Automated carton assembly, leaflet insertion, and tamper-evident sealing are supported by high-speed labeling systems. These systems apply batch, expiry, and serialization data efficiently. We implement 2D Matrix Unit Serialization in full compliance with EU FMD and US DSCSA requirements. This ensures traceability and market readiness across global territories.

Compliance and Standards

Eirgen's packaging facility operates under FDA, EMA, and HPRA standards. It supports both clinical and commercial supply. By integrating packaging with our high-potency CDMO offering, we provide partners with a reliable, compliant, and efficient solution that shortens timelines and strengthens supply chain control.

The Eirgen Advantage

For sponsors developing high-potency therapies, Eirgen offers a clear operational advantage—faster market access through a fully contained, in-house packaging model. This approach not only enhances efficiency but also ensures that we remain committed to innovation and collaboration, which are core to our identity at Eirgen.

Conclusion

In conclusion, packaging is not merely a formality in pharmaceutical development; it is a vital component that influences the entire lifecycle of a product. By choosing Eirgen, you are partnering with a company that prioritizes patient-centricity and is dedicated to bringing complex and high-potency medicines to patients faster. We understand the challenges faced in this industry and are here to support you every step of the way.

Our commitment to innovation, collaboration, and patient-centricity shapes how we communicate with our partners, employees, and the broader community. Together, we can navigate the complexities of pharmaceutical development and ensure that high-potency therapies reach those who need them most.

For more information, please visit our website to explore how we can assist you in your pharmaceutical development journey.